<qa>  What is the primary outcome of the study?This is a prospective, observational study to assess the changes in cognitive functioning, behavior, and functional improvement in Alzheimers disease patients treated with Galantamine who are living at home i.e. not in permanent residential care, and to obtain information regarding usual clinical practice performed by relevant specialists. There will be no experimental component associated with this study and all observational activities will be part of routine care. This study will follow patients with Alzheimers disease, who are currently not in permanent residential care, for a period of 18 months. The three domains of cognition, behavior and function will be evaluated at baseline using the Mini-Mental State Examination MMSE andor ADAS-Cog, the abridged Instrumental Activities of Daily Living IADL and a 14-item behavioral assessment scale. Changes in the 3 domains will be observed after 3, 6, 12 and 18 months of Galantamine therapy through the completion of The Clinician Interview Based Impression of Change CIBIC-Plus, abridged IADL, behavioral changes, and the Mini-Mental State ExaminationADAS-Cog. Primary outcome is to determine changes from baseline in cognition, behavior and function will be assessed after 3, 6, 12, and 18 months as measured by the CIBIC-Plus, abridged IADL, the Mini-Mental State ExaminationADAS-Cog and behavioral changes. The secondary outcome is development of information regarding treatment expectations that can be used for communicating with patients and supporters. Galantamine will be prescribed according to routine clinical practice and as per the Product Information leaflet 